Skip to main content

Table 2 Newly diagnosed cardiovascular disease after ICI initiation

From: Newly diagnosed cardiovascular disease in patients treated with immune checkpoint inhibitors: a retrospective analysis of patients at an academic tertiary care center

Immune Checkpoint Inhibitor Cardiomyopathy, n (%) Heart failure, n (%) Arrhythmia, n (%) Pericardial disease, n (%) Heart block, n (%) Myocarditis, n (%) Any cardiotoxicity, n (%) Median (IQR) time to cardiotoxicity, days
PD-1 inhibitors
 nivolumab (n = 217) 1 (0.46) 10 (4.61) 15 (6.91) 7 (3.23) 6 (2.76) 1 (0.46) 33 (15.21) 52 (37–203)
 pembrolizumab (n = 123) 0 6 (4.88) 3 (2.44) 1 (0.81) 1 (0.81) 0 11 (8.94) 65 (30–175)
PD-L1 inhibitors
 atezolizumab (n = 17) 0 1 (5.88) 2 (11.76) 0 0 0 3 (17.65) 22 (2–172)
 durvalumab (n = 4) 1 (25) 0 0 0 0 0 1 (25.00) 30
CTLA-4 inhibitor
 ipilimumab (n = 13) 0 4 (30.77) 1 (7.69) 0 1 (7.69) 0 6 (46.15) 709 (78–1469)
CTLA-4 + PD-1/PD-L1 inhibitor combination
 ipilimumab + nivolumab (n = 29) 2 (6.9) 1 (3.45) 4 (13.79) 0 1 (3.45) 0 7 (24.14) 95 (11–119)
 ipilimumab + pembrolizumab (n = 7) 0 1 (14.29) 1 (14.29) 0 0 0 1 (14.29) 62
 tremelimumab + durvalumab (n = 3) 0 0 0 0 0 0 0  
PD-1/PD-L1 dual sequential
 nivolumab - > pembrolizumab (n = 4) 0 0 0 0 0 0 0  
 nivolumab - > atezolizumab (n = 3) 0 0 0 0 0 0 0  
 pembrolizumab - > atezolizumab (n = 3) 0 0 0 0 0 0 0  
Three-drug sequential
 ipilimumab + nivolumab - > pembrolizumab (n = 1) 0 0 0 0 0 0 0  
Total (n = 424) 4 (0.94) 23 (5.42) 26 (6.13) 8 (1.89) 9 (2.12) 1 (0.24) 62 (14.62) 63 (30–175)
  1. IQR inter-quartile range